Quest Laboratories Limited — PPTs, 06-06-2025: Investor Presentation

1. Financial Highlights:

Quest Laboratories reported revenue of ₹103.92 Cr, up 25.9% YoY. EBITDA rose modestly by 2.7% to ₹15.98 Cr, with margins contracting to 15.4% from 18.9%. Profit after tax increased 34.4% to ₹13.57 Cr, with PAT margins expanding to 13.1%. Gross profit margin declined sharply to 23.8% from 36.7%, primarily due to higher raw material costs (₹79.16 Cr vs ₹52.24 Cr). Equity rose to ₹81.80 Cr and total assets to ₹121.65 Cr. Operating cash flow was negative at -₹23.48 Cr due to working capital changes.

2. Strategic Initiatives & Growth Drivers:

The company is investing ₹30-35 Cr in USFDA-compliant injectable and capsule manufacturing capacity targeting domestic and export markets. Oncology injectables and six collagen formulations remain in R&D focus. Export sales launched recently, with a notable ₹25 Cr order book from Myanmar and expansion plans in Africa. R&D spend is about 2% of revenue to support product innovation.

3. Business Developments:

Quest is expanding internationally with new orders from Angola and market entries in Cambodia, Kenya, and Nigeria. Manufacturing is scaling up with advanced technology, including lyophilizer systems for injectables. Capsule production is expected to contribute ₹10-12 Cr this year. Continued government partnerships and public tender participation bolster order stability.

4. Market Position & Competitive Advantage:

With 1300+ licensed formulations and 394 active SKUs across tablets, syrups, ointments, and dry forms, Quest enjoys a broad and integrated product portfolio. Strong in-house R&D and infrastructure offer cost and speed advantages. Entry into injectables and capsules aims to capture higher-margin segments and boost presence in regulated markets.

5. Investor Implications:

Quest’s growth outlook looks positive, driven by geographic diversification and capacity expansion. Margin pressure from raw material costs is a challenge but profitability is improving. Execution risk on new facility ramp-up and international scaling warrants monitoring. The company’s broad portfolio and government ties support steady revenues, with injectables and capsules poised as medium-term earnings catalysts.